google-site-verification: googlec7193c3de77668c9.html

Study compares single-inhaler triple therapies for treatment of COPD

Study compares single-inhaler triple therapies for treatment of COPD

For patients with chronic obstructive pulmonary disease (COPD), budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol, according to a study published online Dec. 30 in The BMJ.

William B. Feldman, M.D., M.P.H., from Brigham and Women’s Hospital in Boston, and colleagues compared the effectiveness and safety of budesonide-glycopyrrolate-formoterol, a twice-daily metered dose inhaler, and fluticasone-umeclidinium-vilanterol, a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched pairs of new users.

The researchers found that the incidence of a first moderate or severe COPD exacerbation was higher in patients who received budesonide-glycopyrrolate-formoterol (hazard ratio, 1.09; 95 percent confidence interval, 1.04 to 1.14; number needed to harm, 38) compared with those who received fluticasone-umeclidinium-vilanterol, while the incidence of first admission to hospital with pneumonia was identical between the groups (hazard ratio, 1.00; 95 percent confidence interval, 0.19 to 1.10). Those receiving budesonide-glycopyrrolate-formoterol compared with fluticasone-umeclidinium-vilanterol had a higher risk for a first moderate COPD exacerbation (hazard ratio, 1.07; 95 percent confidence interval, 1.02 to 1.12 ; number needed to harm, 54) and for a first severe COPD exacerbation (hazard ratio, 1.29; 95 percent confidence interval, 1.12 to 1.48; number needed to harm, 97). Similar findings were seen in prespecified sensitivity analyses.

“Our study may provide reassurance to health systems seeking to decrease greenhouse gas emissions by reducing use of metered dose inhalers, because the single-inhaler triple therapy with the lower carbon footprint (the dry powder inhaler, fluticasone-umeclidinium-vilanterol) was also associated with slightly improved clinical outcomes,” the authors write.

Several authors disclosed ties to the pharmaceutical and health information technology industries.

More information:
William B Feldman et al, Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study, BMJ (2024). DOI: 10.1136/bmj-2024-080409
Meng-Ting Wang et al, Environmentally friendly inhaler regimens for COPD, BMJ (2024). DOI: 10.1136/bmj.q2825

Copyright © 2025 HealthDay. All rights reserved.

Citation:
Study compares single-inhaler triple therapies for treatment of COPD (2025, January 3)
retrieved 4 January 2025
from https://medicalxpress.com/news/2025-01-inhaler-triple-therapies-treatment-copd.html

Advertisements

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.




medicalxpress.com

See also  Long COVID patients who lost sense of smell can be helped with surgery

Check Also

Studies reveal how instability may shape infant attention, brain activity and emotional regulation

[ Credit: Unsplash/CC0 Public Domain A baby’s brain is always listening, watching and learning—even when …

New philosophical framework reframes moral distress in health care

[ This type of suffering arises when professionals recognize the ethically appropriate course of action …

Monoclonal antibody targeting interleukin-6 achieves sustained reductions in inflammation biomarkers through six months

[ Credit: Unsplash/CC0 Public Domain The investigational anti-interleukin-6 (IL-6) monoclonal antibody pacibekitug produced sustained reductions …

Leave a Reply

Available for Amazon Prime